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ABSTRACT 
Objective: Aim of the study was to formulate, evaluate and optimize medicated Lip rouge containing acyclovir encapsulated inside a novel vesicular 
carrier, niosome so that the formulation can improve its membrane penetration. Formulating as a cosmetic Lip rouge formulation will also improve 
patient compliance in the treatment of herpes labialis.  
Methods: Acyclovir niosomes were prepared by thin film hydration method. Niosomes were evaluated and were optimized by considering the 
entrapment efficiency and in vitro release profile. The optimized niosomes were incorporated into lipstick, lip balm and lip rouge for selecting the 
best lip formulation. Based on the in vitro release profile, ease of application and properties of prepared formulations lip rouge was selected and 
further evaluations were carried out.  
Results: Among the six formulations of niosomes NF2 has showed 88.49 % entrapment efficiency and 86.97% cumulative drug release in 8 h. The 
formulation was optimized considering both entrapment efficiency and in vitro release. The optimized formulation of niosomes was incorporated 
into Lipstick, lip balm and lip rouge. The evaluation results of lipstick, lip balm and lip rouge for in vitro release suggested lip rouge as the best 
formulation. The percentage cumulative release of drug from optimized lip rouge at the end of 8 h was 84.77%. The percentage cumulative drug 
release in ex vivo studies for 8 h was 60.88 %. 
Conclusion: The results suggested that prepared lip rouge containing acyclovir niosomes can effectively deliver the drug than the marketed 
acyclovir cream and successful therapy of Recurrent Herpes labialis can be achieved. 
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Herpes labialis (cold sores) is a condition which affects the skin and 
mucous membranes (particularly, the lips) that are preceded and 
accompanied by burning pain. The recurrent infections occurring 
due to different stimuli like sunlight, fever, menstruation, etc are 
difficult to manage. Acyclovir is the common antiviral agent that is 
used for the treatment of Herpes labialis. Acyclovir 5% cream is 
used for the treatment of herpes labialis along with oral dosage 
forms like tablets. These formulations show poor therapeutic 
outcome due to the poor bioavailability (15-20%) of oral dosage 
forms and poor penetration of the drug from topical formulations 
across the lip membrane. Acyclovir is a BCS class III Drug having 
limited permeability. Enhancement of penetration of Acyclovir 
through the lip membrane will increase the therapeutic outcome [1]. 
Enhancement of penetration of drugs can be achieved by 
encapsulating such drugs inside a lipophillic vesicular carrier. 
Niosomes have been claimed to improve the topical delivery of 
compounds, by increasing penetration of the active ingredient 
through the site of application.  
Niosomes are nonionic surfactant based unilamellar or 
multilamellar vesicles in which an aqueous solution of solute is 
entirely enclosed by a membrane resulting from the organization of 
surfactant macromolecules as bilayers. It is possible to encapsulate 
hydrophilic as well as lipophophillic drugs in niosomes. The 
lipophilic nature of constituent lipids in niosomes helps in the 
penetration of the drugs encapsulated inside into the deeper tissues 
of the lip [2, 3]. Niosomes are widely used in the formulation of 
cosmetic products like lip balms, creams, liprouge, lipsticks, etc. 
The cosmetic formulations which are applied to the lips include 
lipsticks, lip balms, lip jellies, lip salves, lip gloss, lip rouge etc. These 
formulations impart attractive colour along with gloss to the lips. Lip 
rouge [4] is used as an alternative to lipstick. They are almost 
semisolid or liquid in nature. They can be prepared by incorporating 
pigments in a base that can incorporate the suitable amount of 
aqueous phase. Such a formulation is suitable for incorporating 
niosome encapsulated drugs. The consistency of this type of 
formulation allows easy application with the help of a brush 
attached to the lid of the container. It also helps to achieve better 
permeation of the active medicament into the lip membrane. The 
formulation is a cosmetic with good aesthetic appeal and ease of 
application. The more accurate application of the active ingredient 
to the area involved leads to a more effective treatment of the 
disease. The cosmetic formulation will be more acceptable to the 
patient compared to the existing formulation and this may improve 
patient compliance.  
The aim of the study was to develop medicated lip rouge containing 
niosomal acyclovir for the treatment of recurrent herpes labialis. 
This study was an approach for the development of a formulation 
capable of providing an increased concentration of the drug at the 
dermal tissue for the effective management of cold sores. As the 
formulation is developed by encapsulating the drug inside a 
niosomal carrier which is lipophillic, it may be able to penetrate 
deep into the lip membrane and release the drug at the site of action.  
MATERIALS AND METHODS 
Materials 
Acyclovir was gifted from U square life sciences, Ahmadabad span 60 
and span 80(Nice chemicals kochi, kerala), cholesterol, (central drug 
house pvt. Ltd, New Delhi), dichloromethane (Nice chemicals Pvt. Ltd, 
Kochi), white beeswax (Central drug house Pvt. Ltd, New Delhi), 
carnauba wax (oxford laboratory, mumbai), cetyl Alcohol (Qualigens 
Fine Chemicals, Mumbai), hard paraffin (southern union 
pharmaceuticals pvt. Ltd, Kochi), anhydrous lanolin (Loba chemie Pvt. 
Ltd, Mumbai), white soft paraffin (Southern union pharmaceuticals. 
pvt. Ltd, Kerala), castor oil (Central drug house pvt. Ltd, New Delhi), 
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light liquid paraffin (Nice chemicals pvt. Ltd. kochi), propylparaben 
was gifted from chethana pharmaceuticals Pvt. Ltd. Kerala. 
Methods 
Formulation development 
Preparation of niosomes containing acyclovir by thin film 
hydration method 
Weighed accurately the required quantity of cholesterol, surfactant, 
in a clean and dry round-bottomed flask, dissolved it by adding 
required quantity of dichloromethane. The flask was attached to a 
rotary vaccum evaporator and allowed to rotate at 150 rpm until a 
thin layer of dry film was formed on the inner wall of the flask [3]. 
Dissolved the required quantity of acyclovir in phosphate buffer pH 
7.4 containing a required quantity of 0.1N sodium hydroxide [5].  
The thin film formed on the inner wall of the flask was hydrated with 
this aqueous phase containing the drug. The flask containing niosomes 
was shaken well and placed in a bath sonicator to reduce the size of 
vesicles. Unentrapped drug was removed by centrifugation method 
using a cooling centrifuge at 4 °C and 11000rpm 
 
Table 1: Compositions of the niosomes of acyclovir 
Formulation code Drug: surfactant: cholesterol ratio Drug (g) Span 60 (g) Span 80 (g) Cholesterol (g) 
NF1 1:1:1 1  1 1 
NF2 1:2:1 1  2 1 
NF3 1:1:2 1  1 2 
NF4 1:1:1 1 1  1 
NF5 1:2:1 1 2  1 
NF6 1:1:2 1 1  2 
 
Evaluation of niosomes 
Physical appearance 
All the batches of prepared niosomes were observed visually for 
physical appearance, and homogeneity [6]. 
Drug content and entrapment efficiency 
The unentrapped drug was separated by centrifugation in a cooling 
centrifuge at 11000 rpm and at 4 °C for 30 min [7]. The supernatant was 
separated. The resultant niosomal pellets were taken and a known 
amount of pellets was disrupted by adding 2-propanol and diluted with 
phosphate buffer pH 7.4. The absorbance was measured using UV 
spectrophotometer at λ max 251 nm. The drug content and percentage 
entrapment efficiency was calculated using the following equations 
Percentage entrapment efficiency = weight of entrapped drug
weight of total drug
 X 100 
In vitro drug release study 
The in vitro release studies on niosomal suspension was performed 
using open-ended diffusion tube having an internal diameter of 2.5 
cm and length of about 10 cm which acts as donor compartment. 50 
ml pH 7.4 phosphate buffer was used as the receptor medium. The 
Hi-media dialysis membrane 60 was mounted between the donor 
and receptor compartment [8]. A measured amount of niosomal 
suspension was placed on one side of the membrane. The receptor 
medium was stirred by a magnetic bead fitted to a magnetic stirrer 
at a speed of 600 rpm. At each sampling interval, 2 ml were 
withdrawn and were replaced by equal volumes of fresh receptor 
fluid. The sink condition was maintained throughout the experiment. 
Samples withdrawn were suitably diluted and analyzed 
spectrophotometrically at λmax 251 nm. The percentage drug 
release was calculated using calibration curve of the drug in 
phosphate buffer pH 7.4 containing 0.1N Sodium hydroxide. 
Optimization of niosomes 
Optimization of formula for niosomes was carried out based on the 
results of percentage entrapment efficiency and in vitro drug 
release [9]. 
Microscopic evaluation 
Niosomal suspension was also viewed by a binocular microscope at 
40x magnification, to observe characteristics of suspension by 
spreading a thin layer of niosomal suspension on a slide [9]. 
Vesicle size, size distribution analysis 
The vesicle size of the sample of niosomes was analysed by using 
particle size analyser (Malvern instrument) [9]. 
Zeta potential 
The optimized niosomal dispersions were characterised for zeta 
potential by dynamic light scattering technology using Malvern 
Instruments.
 
Formulation of lip cosmetic formulations containing acyclovir niosomes [10, 11] 
 
Table 2: Composition of lip formulations containing acyclovir niosomes 
S. No. Ingredients  Quantity 
Lipstick Lip balm Lip rouge 
1 White beeswax 15% - - 
2 Hard paraffin - 5% - 
3 Carnauba wax 5% - - 
4 White soft paraffin - 10% 30% 
4 Anhydrous lanolin 30% 30% 35% 
5 Cetyl alcohol 5% - - 
6 Castor oil 35% 30% 15% 
7 Light liquid paraffin - 15% 10% 
8 Strawberry flavour q. s q. s q. s 
9 Carmine red q. s q. s q. s 
10 Propyl paraben 0.05% 0.05% 0.05% 
The required quantity of optimized niosomes was incorporated in all the formulations which will give 5% Acyclovir in the final formulation.  
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Evaluation of lip cosmetic formulations containing acyclovir 
niosomes 
In vitro release study 
The in vitro release of Acyclovir niosome loaded lipstick, lip balm 
and lip rouge were compared using open-ended diffusion tube. 
The capacity of receptor compartment was 50 ml pH 7.4 
phosphate buffer placed in 100 ml beaker. The temperature was 
maintained at 37±0.5 °C.  
The hi media dialysis membrane 60 was mounted between the 
donor and receptor compartment. Accurately weighed quantities 
of formulations were separately applied on one side of the 
membrane. The receptor medium was stirred by a magnetic bead 
fitted to a magnetic stirrer. At each sampling interval, (2 ml) 
were withdrawn and replaced by equal volumes of fresh 
receptor fluid on each occasion. The Sink condition was 
maintained throughout the experiment. Samples withdrawn 
were suitably diluted and analyzed spectro-photometrically at 
λ max
Weighed accurately about 1 gm of lip rouge in a 100 ml standard 
flask and 1 ml of 2-propanol was added to break the niosomal 
vesicles and made up to volume with phosphate buffer pH 7.4 and 
absorbance of the resulting solution was measured at 251 nm [13]. 
 251 nm.  
Optimization of formulations 
Among the three formulations a suitable type of formulation that is 
easy to apply on lips of affected patients, easy to prepare and handle, 
and which on the application will release sufficient quantities of the 
drug and hence provide a better therapeutic effect was selected. In 
vitro drug release profile was also considered. 
Evaluation of optimized medicated lip rouge containing 
Acyclovir niosomes 
Physical appearance 
The prepared lip rouge was evaluated for colour and physical 
appearance 
Spreadability [12] 
The formulation was applied to a glass slide. The time taken by the 
other slide attached to a pan containing fixed weights to slide over a 
particular distance was noted. Spreadability was calculated using 
the formula,  
S = M X L
T
 
Where S is the Spreadability, M is the weight in the pan (tied to the 
upper slide), L is the length moved by the glass slide and T is the 
time taken to separate the slide completely from each other. 
Determination of pH 
pH of the selected formulation was determined using digital pH 
meter at room temperature. 
Determination of viscosity 
The viscosity of the formulation was analysed using Brookfield DV-E 
viscometer using spindle S-64 at various rpm ranging from 2 to 10. 
The value of viscosity was measured in terms of cps. 
Drug content 
Comparison of medicated lip rouge containing acyclovir 
niosomes with marketed formulation  
In vitro permeation study 
The in vitro release of acyclovir niosome loaded lip rouge was 
compared with marketed formulation using open-ended 
diffusion tube which acts as donor compartment. The hi media 
dialysis membrane 60 [14] was mounted between the donor and 
receptor compartment. Accurately weighed lip rouge 
formulation and marketed formulation was suitably applied on 
one side of the membrane. The in vitro release of the acyclovir 
niosome loaded lip rouge was compared with the marketed 
formulation as described in the previous section. 
Ex vivo permeation study 
Accurately weighed quantities of marketed formulation and 
optimized formulation of lip rouge were separately applied on a 
porcine snout membrane [14]. A blank experiment was also 
performed simultaneously. The ex vivo permeation of Acyclovir 
niosome loaded lip rouge was compared with marketed formulation 
using open-ended diffusion tube [15, 16].  
The receptor medium was stirred by a magnetic bead fitted to a 
magnetic stirrer. 2 ml was withdrawn and replaced by equal volumes of 
fresh receptor fluid on each occasion. The Sink condition was maintained 
throughout the experiment. Samples withdrawn were suitably diluted 
and analyzed spectrophotometrically at λmax 251 nm.  
Skin retention study 
After ex vivo permeation studies of prepared Lip rouge dosage form 
and a marketed formulation containing an optimized formulation of 
niosomes [17], the amount of drug in the donor and receptor 
compartments were analysed spectrophotometrically and the 
difference between the above two parameters was considered as the 
drug retained on the porcine skin. 
RESULTS AND DISCUSSION 
Formulation and evaluation of niosomes 
Physical appearance 
All the batches of prepared niosomes appeared as white coloured 
uniform dispersion, without any agglomeration.  
Drug content and entrapment efficiency 
The percentage entrapment efficiency of niosomal formulation 
was found to be greatest for formulations NF2 and NF5. Niosomes 
containing span 60 showed greater percentage entrapment 
efficiency compared to the niosomes made of span 80 in similar 
ratios. 
The nature of the hydrophobic alkyl chain affects the encapsulation 
efficiency of the drug. Vesicles obtained from the long alkyl chain 
surfactants give slightly higher entrapment efficiency than those 
obtained from the shorter alkyl chain surfactants [18].  
This results were found to be in conformance with a previous study 
done by M. A Linghan et al. 
 
Table 3: Drug content and percentage entrapment efficiency 
Formulation code Drug content* % entrapment efficiency (mg) * 
NF1 371.8±1.84 37.47±0.420 
NF2 885.6±2.08 88.49±0.600 
NF3 604.3±1.52 60.40±0.418 
NF4 379.3±2.08 37.98±0.179 
NF5 886.6±1.58 88.63±0.209 
NF6 675.8±2.00 67.63±0.276 
*
 
(n =3) (mean±SD) 
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Table 4: In vitro drug release data of niosome formulations 
Time 
(H) 
Percentage cumulative drug release (% CDR) 
NF1 NF2 NF3 NF4 NF5 NF6 
0 0 0 0 0 0 0 
0.5 23.05±1.14 28.86±1.00 25.94±1.64 28.35±1.07 31.66±1.37 17.69±1.26 
1 38.69±1.11 38.56±1.58 31.11±1.39 37.29±1.12 40.58±2.09 28.66±1.32 
2 47.09±1.73 47.91±2.22 36.08±1.50 45.26±2.08 47.48±1.53 36.34±1.73 
3 52.94±1.94 55.53±2.54 41.43±1.67 51.39±0.91 54.76±1.88 42.03±1.70 
4 57.83±1.73 62.04±1.25 45.06±1.55 56.85±1.04 60.50±1.54 45.23±2.67 
5 62.04±1.21 68.57±1.14 49.78±2.40 60.93±1.09 65.07±1.55 47.84±1.28 
6 67.47±1.51 74.6±1.58 53.43±1.99 64.27±1.49 70.54±1.63 49.74±1.57 
7 70.89±1.45 80.57±1.32 57.17±1.28 67.75±2.08 75.48±1.11 51.32±1.73 
8 72.73±2.61 86.97±1.28 58.62±1.03 69.81±1.94 77.73±1.80 52.74±1.75 
*
 
In vitro drug release study  
Formulation NF2 showed the highest percentage cumulative drug 
release at the end of 8 h All niosome formulations containing span 
80 showed the better release of the drug compared to the 
corresponding niosome formulations made in the similar ratios of 
span 60.  
The release of drug from niosomes depends upon the chain length of 
surfactant and concentration of cholesterol. This can be explained by 
the fact that niosomes exhibit an alkyl chain length-dependent 
release. The higher the chain length, the lower the release rate. span 
60 thus retards the drug release. This is in accordance with a 
previous study done by Ruckmani et al. (2000) [19]. This can be 
explained by the fact that niosomes exhibit an alkyl chain length-
dependent release. The higher the chain length, the lower the 
release rate (Devaraj et al., 2002) [20] But in the case of niosomes 
containing span 80, the highest release of 86.97% was obtained. This 
higher release rate may be due to the unsaturation present in alkyl 
chain of span 80 which causes loosening in the structure leading to 
increased drug release. Span 60 have the same head group with 
different alkyl chain but span 80 has an unsaturated alkyl chain so 
the double bond made the chain bend. This means that the adjacent 
molecules cannot be tight when they form the membrane of niosome 
and might be the reason for the higher drug release from span 80 
systems.  
Optimization of niosomal formulations 
(n =3) (mean±SD) 
From the evaluation results of 6 formulations of Niosomes (NF1, 
NF2, NF3, NF4, NF5, NF6) optimization was done based on the 
results of Entrapment efficiency and In vitro drug release studies. 
The results of entrapment efficiency of formulation NF2 and NF5 
showed the highest values of 88.49% and 88.63% respectively. But 
in vitro release of 86.97% was exhibited by formulation NF2. 
Therefore NF2 was selected for further studies. 
Microscopic evaluation 
The optimized niosomal suspension (NF2) was observed under a 
binocular microscope. The fully formed niosome vesicles were 
visible and the image is as shown in fig. 4. 
 
 
Fig. 1: Microscopic image of Niosomes under binocular 
microscope 
 
Vesicle size, size distribution analysis 
The particle size of the sample of niosomes was analysed by using 
particle size analyser (malvern instrument). The results of particle 
size analysis of blank niosomes and optimized formulation NF2 are 
shown in fig. 
 
 
Fig. 2: Vesicle size and size distribution of blank niosomes 
Rajalakshmi et al. 
Int J App Pharm, Vol 9, Issue 6, 2017, 21-27 
25 
 
Fig. 3: Vesicle size and size distribution of optimized niosomal formulation NF2 
 
Polydispersity Index (PdI) is a dimensionless measure of the broadness 
of the size distribution calculated from the cumulants analysis. In the 
zetasizer software, it ranges from 0 to 1 values greater than 1 indicate 
that the distribution is so polydisperse the sample may not be suitable 
for measurement by dynamic light scattering. PdI of blank niosomes and 
optimized niosomes NF2 were found to be 0.419 and 0.469 respectively. 
 
Table 5: Standards for polydispersity index 
Polydispersity index value Comments 
<0.05 Normally encountered with particls made to be monodisperse 
<0.08 Nearly monodisperse sample 
0.08 to 0.7 A mid-range value of PdI. 
>0.7 Indicates a very broad distribution of particle sizes 
The results suggested a moderately broad size distribution of particles 
 
Zeta potential  
The optimized niosomal dispersion was characterised for zeta 
potential by dynamic light scattering technology using malvern 
Instruments. Zeta potential was found to be-53.5mV.  
It indicates good stability of niosomal dispersion. 
Formulation and evaluation of lipstick, lip balm and lip rouge 
containing optimized acyclovir niosomes 
Optimized niosomal formulation of acyclovir was incorporated into 
lipstick base. Similarly, lip balm and lip rouge were prepared by 
incorporating optimized niosomal formulation of acyclovir. The 
prepared formulations were evaluated for in vitro release profile. 
 
Table 6: In vitro drug release data of lipstick, lip balm and lip rouge 
Time 
(H) 
Percentage cumulative drug release* (%CDR) 
Lipstick Lip balm Lip rouge 
0 0 0  0 
0.5 3.07±1.01 4.56±1.32 29.51±2.47 
1 3.77±1.22 11.04±1.85 39.53±1.59 
2 4.42±0.70 11.60±1.73 46.71±0.86 
3 5.10±0.72 13.05±1.42 55.64±2.02 
4 6.86±0.72 13.98±1.70 60.48±2.38 
5  7.24±1.17 13.93±1.99 69.72±2.07 
6 9.82±1.99 17.30±0.99 75.66±2.03 
7 10.79±1.97 22.61±2.05 80.50±1.55 
8 15.10±2.11 24.28±2.94 83.23±1.79 
*
 
(n =3) (mean±SD) 
From the experimental data, it was found that lip rouge showed the 
highest percentage cumulative drug release compared to lip balm 
and lipstick. This suggested the possibility of formulating lip rouge 
for better release of drug and hence better therapeutic effect. 
Optimization 
Comparing the pharmaceutical elegance, ability to apply correct 
dose at the site of application and in vitro drug release profiles of the 
three types of formulations, it was found that the lip rouge 
formulation is superior to lip balm and lipstick. The lip rouge 
formulation had shown the better release of drug after 8 h of in vitro 
diffusion study. The results suggested the better release of drug 
from lip rouge among the three types of lip formulations. 
Evaluation of optimized lip rouge containing acyclovir niosomes 
Physical appearance 
The prepared lip rouge was evaluated for physical appearance. The 
formulation was uniform in appearance without agglomerates. 
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Determination of spreadability  
The spreadability data obtained for the optimized formulation of lip 
rouge was 8.043±1.02. This suggested that it has a good spreadability so 
that it is possible to apply the formulation easily on the lips with the 
brush or by roll-on applicator. 
Determination of pH 
pH of the optimized formulation of lip rouge was found to be 
7.2±0.22. The results suggested that the lip rouge could be 
compatible with lips on application. 
Table 7: Determination of viscosity 
Sample Viscosity(cps) 
Lip rouge 3452±1.15 
 
Drug content 
Drug content of lip rouge containing the optimized formulation of 
niosomes (NF2) was found to be 46.28±1.24 mg/gm 
  
Table 8: comparison of in vitro drug release data of optimized lip rouge with marketed formulation 
Time (h) Percentage cumulative drug release (% CDR) (mean±SD) 
Lip rouge (NF2)  Marketed product 
0 0 0 
0.5 25.06±1.51 4.11±0.30 
1 39.18±1.41 9.88±1.39 
2 50.48±1.98 11.89±1.43 
3 60.38±0.55 14.44±1.26 
4 68.59±1.21 15.23±0.80 
5 74.38±0.70 21.99±1.56 
6 78.94±1.34 28.22±2.36 
7 80.93±1.49 31.89±1.73 
8 84.77±1.26 35.40±2.47 
 
Comparison of medicated lip rouge containing acyclovir 
niosomes with marketed formulation 
In vitro drug release study 
Ex-vivo permeability study 
Ex vivo permeability study using porcine snout membrane was 
carried out for optimized lip rouge formulation and for marketed 
acyclovir cream. In the case of ex vivo permeability study, lip rouge 
showed 60% drug release while it was 25% drug release for the 
marketed cream formulation. 
Since drug release from formulated lip rouge is higher than that of 
the marketed formulation it will have increased therapeutic effect 
than the marketed formulation. 
CONCLUSION 
The goal of present study was to formulate a topical dosage form for 
the treatment of herpes labialis (cold sores) that will improve the 
penetration properties of the drug acyclovir which is a BCS class III 
drug, having a very low permeability to the dermal tissue. Acyclovir 
is a guanosine analog antiviral drug which is commonly used for 
herpes infections. Lipid vesicular carrier, niosome was used as a 
carrier for penetration enhancement of the drug, acyclovir. Since 
formulation of the dosage form as a cosmetic preparation can 
improve the patient acceptance, in this study acyclovir encapsulated 
niosomes were formulated as a lip rouge.  
The formulated lip rouge containing acyclovir niosomes showed 
better penetration of drug than conventional formulation. Hence it 
can be concluded that the prepared lip rouge formulation showed 
better physicochemical properties and drug release compared to the 
marketed formulation. Since it is a cosmetic formulation with 
elegant appearance, colour and flavour, it will have a good cosmetic 
appeal on the application as well as improved therapeutic effect in 
the management of recurrent herpes labialis. 
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